Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5610013 | 0.94 | SMN1; SMN2 (0.68) | SMN1; SMN2USP2TSHRRAB9ANPC1 | |
| SCHEMBL14685205 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2USP2TSHRRAB9ANPC1 | |
| SCHEMBL6868621 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2USP2TSHRRAB9ANPC1 | |
| SCHEMBL3746825 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2USP2TSHRRAB9ANPC1 | |
| SCHEMBL31248989 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2USP2TSHRRAB9ANPC1 | |
| SCHEMBL18997842 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2USP2TSHRRAB9ANPC1 | |
| SCHEMBL9695968 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2USP2TSHRRAB9ANPC1 | |
| SCHEMBL11995138 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2USP2TSHRRAB9ANPC1 | |
| SCHEMBL12089187 | 0.78 | SMN1; SMN2 (0.65) | SMN1; SMN2USP2TSHRRAB9ANPC1 | |
| SCHEMBL103809 | 0.76 | RAB9A (0.60) | SMN1; SMN2USP2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603957-B1 | POLYMERISATION AND OLIGOMERISATION CATALYSTS | INEOS SALES UK LTD (GB) | 2015-10-28 | — | — | EP | disclosed |
| US-7229943-B2 | Polymerisation and oligomerisation catalysts | INNOVENE EUROPE LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-20060094588-A1 | Polymerisation and oligomerisation catalysts | BARCLAYS BANK PLC (GB) | 2006-05-04 | — | — | US | disclosed |
| EP-1603957-A1 | POLYMERISATION AND OLIGOMERISATION CATALYSTS | Innovene Europe Limited (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083263-A1 | POLYMERISATION AND OLIGOMERISATION CATALYSTS | INNOVENE EUROPE LIMITED (GB) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094588-A1 | Polymerisation and oligomerisation catalysts | CCNA1, AP2M1, AP2A1 | SMN1; SMN2 3757/4885USP2 3094/4885TSHR 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.